Cost of care in first line advanced NSCLC patients: Chemotherapy vs targeted therapy

被引：0
|
作者：
Radtchenko, J. [1 ]
Korytowsky, B. [2 ]
Tuell, K. [3 ]
Bhor, M. [1 ]
Feinberg, B. [4 ]
机构：
[1] Cardinal Hlth, HEOR, Dublin, OH USA
[2] Bristol Myers Squibb, Outcomes Res, Princeton, NJ USA
[3] Bristol Myers Squibb, HSOR, Princeton, NJ USA
[4] Cardinal Hlth, Oncol, Dublin, OH USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.73
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1273P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone as First-Line Therapy for NSCLC
    Gadgeel, Shirish
    Gandhi, Leena
    Borghaei, Hossein
    Socinski, Mark A.
    Gubens, Matthew A.
    Stevenson, James
    Sequist, Lecia V.
    Yang, James Chih-Hsin
    Papadimitrakopoulou, Vassiliki
    Bourque, Jennifer
    Bachman, Robert D.
    Ge, Joy Yang
    Im, Ellie
    Patnaik, Amita
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S428 - S428
  • [2] First line chemotherapy in advanced or metastatic NSCLC
    Rinaldi, M.
    Cauchi, C.
    Gridelli, C.
    ANNALS OF ONCOLOGY, 2006, 17 : V64 - V67
  • [3] Weekly paclitaxel and paraplatin as first line chemotherapy in patients with advanced NSCLC
    El-Sherbieny, E
    El-Halim, IA
    Shanashawy, H
    El-Khply, N
    LUNG CANCER, 2005, 49 : S390 - S390
  • [4] Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer
    Garrido, Marcelo
    Fonseca, Paula J.
    Maria Vieitez, Jose
    Frunza, Madalina
    Lacave, Angel J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (08) : 887 - 900
  • [5] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
    Ramalingam, S.
    Reungwetwattana, T.
    Chewaskulyong, B.
    Dechaphunkul, A.
    Lee, K. H.
    Imamura, F.
    Nogami, N.
    Ohe, Y.
    Cheng, Y.
    Cho, B. C.
    Cho, E. K.
    Vansteenkiste, J. F.
    Voon, P. J.
    Zhou, C.
    Gray, J.
    Hodge, R.
    Rukazenkov, Y.
    Soria, J-C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC
    Lu, S.
    Yu, Y.
    Yu, X.
    Hu, Y.
    Ma, Z.
    Li, X.
    Zhuang, W.
    Liu, Y.
    Li, W.
    Cui, J.
    Wang, D.
    Liao, W.
    Wang, M.
    Zhou, J.
    Wang, Z.
    Sun, Y.
    Gao, J.
    Bao, Y.
    Liang, L.
    Wang, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S816 - S817
  • [7] Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?
    Zheng, Yulong
    Xu, Nong
    Zhou, Jianying
    LANCET ONCOLOGY, 2013, 14 (11): : E438 - E438
  • [8] Bevacizumab in the first-line therapy of advanced NSCLC
    Hasenoehrl, Norbert
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2007, 157 (21-22) : 576 - 578
  • [9] Sparing Treatment with Cytostatics for Patients with advanced NSCLC Dual Immunotherapy and Chemotherapy Combination is approved as First-line Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 70 - 70
  • [10] Osimertinib (OSI) vs Standard of Care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
    Bischoff, H. G.
    Rueckert, A.
    Reinmuth, N.
    Grohe, C.
    Bohnet, S.
    zum Bueschenfelde, C. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 187 - 187
12345